Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis

PLoS One. 2016 Sep 7;11(9):e0161727. doi: 10.1371/journal.pone.0161727. eCollection 2016.

Abstract

Objective: To estimate cut-off points and to establish response criteria for the Hospital Universitario La Princesa Index (HUPI) in patients with chronic polyarthritis.

Methods: Two cohorts, one of early arthritis (Princesa Early Arthritis Register Longitudinal [PEARL] study) and other of long-term rheumatoid arthritis (Estudio de la Morbilidad y Expresión Clínica de la Artritis Reumatoide [EMECAR]) including altogether 1200 patients were used to determine cut-off values for remission, and for low, moderate and high activity through receiver operating curve (ROC) analysis. The areas under ROC (AUC) were compared to those of validated indexes (SDAI, CDAI, DAS28). ROC analysis was also applied to establish minimal and relevant clinical improvement for HUPI.

Results: The best cut-off points for HUPI are 2, 5 and 9, classifying RA activity as remission if ≤2, low disease activity if >2 and ≤5), moderate if >5 and <9 and high if ≥9. HUPI's AUC to discriminate between low-moderate activity was 0.909 and between moderate-high activity 0.887. DAS28's AUCs were 0.887 and 0.846, respectively; both indices had higher accuracy than SDAI (AUCs: 0.832 and 0.756) and CDAI (AUCs: 0.789 and 0.728). HUPI discriminates remission better than DAS28-ESR in early arthritis, but similarly to SDAI. The HUPI cut-off for minimal clinical improvement was established at 2 and for relevant clinical improvement at 4. Response criteria were established based on these cut-off values.

Conclusions: The cut-offs proposed for HUPI perform adequately in patients with either early or long term arthritis.

MeSH terms

  • Aged
  • Antirheumatic Agents / administration & dosage*
  • Area Under Curve
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / pathology
  • Blood Sedimentation
  • C-Reactive Protein / metabolism*
  • Erythrocytes / pathology
  • Female
  • Guidelines as Topic
  • Hospitals, University
  • Humans
  • Male
  • Middle Aged
  • Remission Induction
  • Severity of Illness Index
  • Translational Research, Biomedical*

Substances

  • Antirheumatic Agents
  • C-Reactive Protein

Grants and funding

Support was provided by grants RD12/0009/0017 and PI14/00442 to IG-A from the Ministerio de Economia y Competitividad (Instituto de Salud Carlos III) and co-funded by Fondo Europeo de Desarrollo Regional (FEDER). The EMECAR study was funded by the Spanish Society of Rheumatology, the Spanish Foundation of Rheumatology, and by an independent research grant from Aventis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.